AKT1 and ovarian carcinoma: Afuresertib (GSK2110183) is an oral ATP competitive pan-AKT inhibitor that has shown a tolerable safety profile and some clinical efficacy in multiple myeloma, Langerhans cell histiocytosis, recurrent platinum-resistant ovarian cancer in combination with carboplatin and paclitaxel; however, its combination with ofatumumab did not show benefit over single-agent ofatumumab [199,200,201,202].